Karin Havenith

1.3k citations
27 papers · 988 · 1 hit paper · h-index 12

Impact in

Papers in

Karin Havenith

27 papers receiving 960 citations

Karin Havenith's Hit Papers

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 355 citations
3550+1+3Years since publication100200300

Peers

Karin Havenith
Comparison fields: 5 of 47
  • Pathology and Forensic Medicine 472
  • Oncology 252
  • Radiology, Nuclear Medicine and Imaging 185
  • Immunology 64
  • Hematology 40
Replace Sreeni Yalamanchili with:
Sreeni Yalamanchili United States
Megan Marie O'Meara United States
David John Lewis United States
Glenn C. Michelson United States
Laurence Hatteville France
Elena Lasorsa United States
Denise McLain United States
Maria Badillo United States
R N Sridhara United States
Asha Ramanunni United States
Karin Havenith relative to Sreeni Yalamanchili United States Sreeni Yalamanchili's profile →
Citations per field
00.5×1.5×2×2.3×
Sreeni Yalamanchili · 1×
Citations per year

Countries citing papers authored by Karin Havenith

Since Specialization
Citations

This map shows the geographic impact of Karin Havenith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Havenith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Havenith more than expected).

Fields of papers citing papers by Karin Havenith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Havenith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Havenith. The network helps show where Karin Havenith may publish in the future.

Co-authors

The 25 scholars most cited alongside Karin Havenith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karin Havenith Line = papers co-authored together Karin Havenith links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Hit paper breakdown →
2021355
2 2020145
3 201986
4 202172
5 202070
6 199746
7 202046
8 202033
9 201615
10 199512
11 201612
12 202412
13 202411
14 201510
15 202410
16 20178
17 20177
18 20237
19 20216
20 20226

About Karin Havenith

Karin Havenith is a scholar working on Pathology and Forensic Medicine, Oncology, Immunology, Radiology, Nuclear Medicine and Imaging and Organic Chemistry, having authored 27 papers that have together received 988 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers), Cancer Immunotherapy and Biomarkers (2 papers), T-cell and B-cell Immunology (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Toxin Mechanisms and Immunotoxins (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (472 citations), Oncology (252 citations), Radiology, Nuclear Medicine and Imaging (185 citations), Immunology (64 citations) and Hematology (40 citations). Karin Havenith has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Jay Marshall Feingold, Mehdi Hamadani, Paolo Fabrizio Caimi, John A. Radford, David Ungar, Melhem Solh, Carmelo Carlo‐Stella, Brad S. Kahl, Kirit M. Ardeshna and Shui Xiang He. Their work appears in journals such as Blood, Hematological Oncology, Blood Advances, The Lancet Oncology and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact